Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Berry

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
Trials|May 26, 2021
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
The Lancet. Oncology|July 19, 2023
Common Sense Oncology: outcomes that matterChristopher M Booth, Manju Sengar, Aaron Goodman, et al.
Current Oncology (Toronto, Ont.)|June 2, 2021
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019Joanna Gotfrit, Rachel Goodwin, Timothy Asmis, et al.
Annals of the American Thoracic Society|April 9, 2020
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and DesignDerek C Angus, Scott Berry, Roger J Lewis, et al.
JAMA|January 18, 2022
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical TrialJeffrey S Berger, Lucy Z Kornblith, Michelle N Gong, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Research Square|July 1, 2024
Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP): study protocol for a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose, adult survivors of after out-of-hospital cardiac arrestWilliam Meurer, Florian Schmitzberger, Sharon Yeatts, et al.
Contemporary Clinical Trials|June 13, 2022
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, J Ryan Bariola, Tami E Minnier, et al.
JAMA Network Open|July 14, 2022
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness TrialDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Trials|July 23, 2024
Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP): study protocol for a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose, adult survivors of after out-of-hospital cardiac arrestWilliam J Meurer, Florian F Schmitzberger, Sharon Yeatts, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
Trials|May 26, 2021
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
The Lancet. Oncology|July 19, 2023
Common Sense Oncology: outcomes that matterChristopher M Booth, Manju Sengar, Aaron Goodman, et al.
Current Oncology (Toronto, Ont.)|June 2, 2021
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019Joanna Gotfrit, Rachel Goodwin, Timothy Asmis, et al.
Annals of the American Thoracic Society|April 9, 2020
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and DesignDerek C Angus, Scott Berry, Roger J Lewis, et al.
JAMA|January 18, 2022
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical TrialJeffrey S Berger, Lucy Z Kornblith, Michelle N Gong, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Research Square|July 1, 2024
Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP): study protocol for a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose, adult survivors of after out-of-hospital cardiac arrestWilliam Meurer, Florian Schmitzberger, Sharon Yeatts, et al.
Contemporary Clinical Trials|June 13, 2022
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, J Ryan Bariola, Tami E Minnier, et al.
JAMA Network Open|July 14, 2022
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness TrialDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Trials|July 23, 2024
Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP): study protocol for a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose, adult survivors of after out-of-hospital cardiac arrestWilliam J Meurer, Florian F Schmitzberger, Sharon Yeatts, et al.
Pageof 15